Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

long-term condition

- PMLiVE

Italy investigates Novartis vaccine after death toll reaches 13

Firms insist on the Fluad's safety, with 65 million doses given in the last 17 years

- PMLiVE

AIDS pandemic now at ‘the beginning of the end’

ONE Campaign says drug access is making the difference, but there's still more to do

- PMLiVE

AZ and Lilly start BACE inhibitor trial in Alzheimer’s

Early trials show promise for the BACE inhibitor AZD3293

- PMLiVE

Novartis’ Gilenya fails in difficult-to-treat form of MS

Drug no better than placebo as a treatment for primary progressive multiple sclerosis

- PMLiVE

Two new hires at Couch

And agency moves to Manchester

- PMLiVE

The challenge of poor adherence in type 2 diabetes

How can pharma help address this growing problem?

- PMLiVE

AZ and Cancer Research UK to collaborate on new medicines

Charity’s scientists to be given access to pharma company’s molecule library

UK flag

UK lags behind other countries in use of branded drugs

ABPI claims use of innovative new treatments is lower than international average in seven out of 11 classes

EU flag

Boehringer’s Vargatef approved in the EU for lung cancer

Marks company’s second oncology drug to hit market

- PMLiVE

Novartis’ heart failure drug on EMA’s fast track

Candidate is the first cardiovascular drug to get accelerated review in the EU

- PMLiVE

NICE overturns negative Glivec guidance

Recommends drug for reimbursement in GIST four years after rejection

- PMLiVE

Teva board elects Yitzhak Peterburg as chairman

He succeeds Phillip Frost

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links